These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34340615)

  • 1. Formulation of carteolol chitosomes for ocular delivery: formulation optimization,
    Zafar A; Alruwaili NK; Imam SS; Alsaidan OA; Alharbi KS; Yasir M; Elmowafy M; Ansari MJ; Salahuddin M; Alshehri S
    Cutan Ocul Toxicol; 2021 Dec; 40(4):338-349. PubMed ID: 34340615
    [No Abstract]   [Full Text] [Related]  

  • 2. Formulation of Chitosan Polymeric Vesicles of Ciprofloxacin for Ocular Delivery: Box-Behnken Optimization, In Vitro Characterization, HET-CAM Irritation, and Antimicrobial Assessment.
    Ameeduzzafar ; Alruwaili NK; Imam SS; Alotaibi NH; Alhakamy NA; Alharbi KS; Alshehri S; Afzal M; Alenezi SK; Bukhari SNA
    AAPS PharmSciTech; 2020 Jun; 21(5):167. PubMed ID: 32504176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating The Retention Potential of Chitosan Nanoparticulate Gel: Design, Development,
    Kaul S; Jain N; Pandey J; Nagaich U
    Recent Pat Antiinfect Drug Discov; 2020; 15(1):41-67. PubMed ID: 31612834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Ciprofloxacin-Loaded Bilosomes In-Situ Gel for Ocular Delivery: Optimization, In-Vitro Characterization, Ex-Vivo Permeation, and Antimicrobial Study.
    Alsaidan OA; Zafar A; Yasir M; Alzarea SI; Alqinyah M; Khalid M
    Gels; 2022 Oct; 8(11):. PubMed ID: 36354595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clarithromycin-Loaded Ocular Chitosan Nanoparticle: Formulation, Optimization, Characterization, Ocular Irritation, and Antimicrobial Activity.
    Bin-Jumah M; Gilani SJ; Jahangir MA; Zafar A; Alshehri S; Yasir M; Kala C; Taleuzzaman M; Imam SS
    Int J Nanomedicine; 2020; 15():7861-7875. PubMed ID: 33116505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation design and optimization of cationic-charged liposomes of brimonidine tartrate for effective ocular drug delivery by design of experiment (DoE) approach.
    Soni PK; Saini TR
    Drug Dev Ind Pharm; 2021 Nov; 47(11):1847-1866. PubMed ID: 35484943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits.
    Ameeduzzafar ; Ali J; Bhatnagar A; Kumar N; Ali A
    Int J Biol Macromol; 2014 Apr; 65():479-91. PubMed ID: 24530326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients.
    Renard P; Kovalski JL; Cochereau I; Jaulerry S; Williamson W; Elena PP; Lablache Combier M; Allaire C; Siou-Mermet R
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1221-7. PubMed ID: 16003515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.
    El-Kamel A; Al-Dosari H; Al-Jenoobi F
    Drug Deliv; 2006; 13(1):55-9. PubMed ID: 16401594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular hypotensive efficacy and safety of once daily carteolol alginate.
    Demailly P; Allaire C; Trinquand C;
    Br J Ophthalmol; 2001 Aug; 85(8):921-4. PubMed ID: 11466245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement in Corneal Permeability of Dissolved Carteolol by Its Combination with Magnesium Hydroxide Nanoparticles.
    Nagai N; Yamaoka S; Fukuoka Y; Ishii M; Otake H; Kanai K; Okamoto N; Shimomura Y
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
    Yamamoto T;
    Nippon Ganka Gakkai Zasshi; 2007 Jun; 111(6):463-72. PubMed ID: 17601060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential use of novel chitosan-coated deformable liposomes in an ocular drug delivery system.
    Chen H; Pan H; Li P; Wang H; Wang X; Pan W; Yuan Y
    Colloids Surf B Biointerfaces; 2016 Jul; 143():455-462. PubMed ID: 27037783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailored nanostructured platforms for boosting transcorneal permeation: Box-Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization.
    Elsayed I; Sayed S
    Int J Nanomedicine; 2017; 12():7947-7962. PubMed ID: 29133980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulus Responsive Ocular Gentamycin-Ferrying Chitosan Nanoparticles Hydrogel: Formulation Optimization, Ocular Safety and Antibacterial Assessment.
    Alruwaili NK; Zafar A; Imam SS; Alharbi KS; Alotaibi NH; Alshehri S; Alhakamy NA; Alzarea AI; Afzal M; Elmowafy M
    Int J Nanomedicine; 2020; 15():4717-4737. PubMed ID: 32636627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Ex Vivo Evaluation of Moxifloxacin Nanostructured Lipid Carrier Enriched In Situ Gel for Transcorneal Permeation on Goat Cornea.
    Gade S; Patel KK; Gupta C; Anjum MM; Deepika D; Agrawal AK; Singh S
    J Pharm Sci; 2019 Sep; 108(9):2905-2916. PubMed ID: 30978345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: ex-vivo transcorneal permeation, corneal toxicity and irritation testing.
    Pathak MK; Chhabra G; Pathak K
    Drug Dev Ind Pharm; 2013 May; 39(5):780-90. PubMed ID: 22873799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gel in core carbosomes as novel ophthalmic vehicles with enhanced corneal permeation and residence.
    Moustafa MA; El-Refaie WM; Elnaggar YSR; Abdallah OY
    Int J Pharm; 2018 Jul; 546(1-2):166-175. PubMed ID: 29778824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization to development of chitosan decorated polycaprolactone nanoparticles for improved ocular delivery of dorzolamide: In vitro, ex vivo and toxicity assessments.
    Shahab MS; Rizwanullah M; Alshehri S; Imam SS
    Int J Biol Macromol; 2020 Nov; 163():2392-2404. PubMed ID: 32979440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.